Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Palatin Technologies Inc is a biotechnology business based in the US. Palatin Technologies shares (PTN) are listed on the NYSE MKT and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $5.73 |
|---|---|
| 52-week range | $4.00 - $24.00 |
| 50-day moving average | $6.62 |
| 200-day moving average | $9.22 |
| Wall St. target price | $65.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.16 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.73 from 2022-09-27
| 1 week (2022-09-21) | -27.74% |
|---|---|
| 1 month (2022-08-26) | 2,692.40% |
| 3 months (2022-06-28) | 1,976.09% |
| 6 months (2022-03-28) | 1,264.29% |
| 1 year (2021-09-28) | 1,126.19% |
|---|---|
| 2 years (2020-09-28) | 1,119.15% |
| 3 years (2019-09-27) | 545.71% |
| 5 years (2017-09-28) | 768.18% |
| Revenue TTM | $1.5 million |
|---|---|
| Gross profit TTM | $-20,076,506 |
| Return on assets TTM | -44.25% |
| Return on equity TTM | -109.83% |
| Profit margin | 0% |
| Book value | $1.76 |
| Market capitalisation | $62 million |
TTM: trailing 12 months
We're not expecting Palatin Technologies to pay a dividend over the next 12 months.
Palatin Technologies's shares were split on a 1:25 basis on 30 August 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Palatin Technologies shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Palatin Technologies shares which in turn could have impacted Palatin Technologies's share price.
Over the last 12 months, Palatin Technologies's shares have ranged in value from as little as $4 up to $24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Palatin Technologies's is 1.1191. This would suggest that Palatin Technologies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Palatin Technologies, Inc. , a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.